Harbin biomedical industry to build rapid escalation platform

 Harbin Municipal Science and Technology Bureau held a school-enterprise matchmaking, Harbin bio-pharmaceutical industry, build a platform for the rapid escalation of Harbin bio-pharmaceutical industry.

    The signing of most of the projects belong to the National Key New Drug Creation. Heilongjiang University of Chinese Medicine, Heilongjiang Sunflower Pharmaceutical Co., Ltd. signed the "the liver tablets secondary development", through the study of the mechanism of action, efficacy and material basis, can greatly improve product quality; Harbin Medical University, Harbin Fu Wales special Biological Engineering Co., Ltd. signed the "new heart disease small molecule nucleic acid warning serum markers kit, in patients with heart disease, early diagnosis and effective in preventing sudden cardiac death; Medicine Research Institute of Heilongjiang Province and Harbin, rain pharmaceutical Group Co., Ltd. complex Fangqing Long clothing capsule "project contracted with a high rate of anti-tumor, analgesic effect, improve immunity" one three features, through the application of modern extraction process to solve the high toxicity of the key technologies bottleneck, the leading domestic level; Heilongjiang University of Chinese Medicine, Chinese Medicine Factory of Harbin Pharmaceutical Group signed five agreements, including "cranberries capsules" projects dose is small, efficient, low toxicity, phase I clinical study is currently being carried out.